Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)

Next Previous
Trial Profile

An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs PhOx 430 (Primary)
  • Indications Advanced breast cancer; Glioblastoma; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Acronyms PhAST; PhAST Trial
  • Sponsors Phost'in Therapeutics

Most Recent Events

  • 02 May 2024 Planned number of patients changed from 146 to 149.
  • 02 May 2024 Planned End Date changed from 31 Jul 2026 to 31 Jul 2027.
  • 02 May 2024 Planned primary completion date changed from 30 Jun 2023 to 8 Jul 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top